Company Overview - RAPT Therapeutics is focused on developing transformative therapies for high-value inflammatory disorders [3] - The company's lead asset, ozureprubart, is a next-generation omalizumab bio-better anti-IgE designed for less frequent dosing and greater compliance [3] Market Opportunity - The potential market for ozureprubart includes food allergies and other allergic disorders, with estimated market opportunities exceeding $40 billion and $5 billion in the United States, respectively [4] - The company reported data from a Phase II study in patients with chronic spontaneous urticaria, demonstrating 16-week durability and supporting a best-in-class profile across multiple allergic disorders [4] Future Milestones - RAPT Therapeutics has multiple anticipated milestones over the next couple of years related to the development of ozureprubart [4]